Why the study?
While cancer patients face an elevated bleeding risk and platelets play a key role, safe thresholds for prophylactic platelet transfusion are mainly described in hematological malignancies, with sparse knowledge in solid tumors.
Is platelet count or function associated with bleeding risk in adult cancer patients?
Population
52 studies of adult cancer patients with hematological malignancy (n = 31), solid tumors (n = 11), or both (n = 10)
Comparison
Platelet count (n = 40) or function (n = 12) and bleeding
Design
PRISMA-guided systematic review
Authors
Loading...
Supports prophylactic transfusion thresholds in hematological malignancies; extends evidence to platelet function while leaving gaps for solid tumors.
Is platelet count or function associated with bleeding risk in adult cancer patients?
This systematic review supports current guidelines for prophylactic platelet transfusions at counts ≤ 10 × 10^9/L in hematological cancer patients, while highlighting a lack of evidence for solid tumors and the potential value of platelet function testing.
Larsen et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: